The content on this site is intended for healthcare professionals only
Dr Robert Motzer presents his study of the results from the randomised, phase 3 CheckMate 914 trial. The study explores adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localised renal cell carcinoma (RCC) at high risk of relapse after nephrectomy.
CheckMate 914 key inclusion criteria included: radical or partial nephrectomy with negative surgical margins > 4 and ≤ 12 weeks before randomisation.
The results demonstrated that patients with localised RCC at high risk of relapse after nephrectomy did not meet the primary endpoint of DFS.
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Olaparib plus ceralasertib might benefit paediatric cancer patients with DNA repair-deficient tumours
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity
Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC
